Clinical trial
Rifaximin for the Treatment of Irritable Bowel Syndrome
NCT00259155 · Cedars-Sinai Medical Center, Other · Completed
Key facts
| NCT number | NCT00259155 |
|---|---|
| Title | Rifaximin for the Treatment of Irritable Bowel Syndrome |
| Official title | Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth and IBS: Double Blind Randomized Controlled Trial (Multicenter Trial) |
| Lead sponsor | Cedars-Sinai Medical Center, Other |
| Collaborators | University of Chicago Bausch Health Americas, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | Rifaximin |
| Enrollment | 92 |
| Start date | Jul 1, 2003 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Nov 29, 2005 |
| Last update posted | Mar 18, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: